A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peplin
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is male or female and at least 18 years of age
Female patients must be of either:
* Non-childbearing potential, post-menopausal
* Childbearing potential, provided there are negative serum and urine pregnancy test results prior to study treatment, to rule out pregnancy
You may not be if
Cosmetic or therapeutic procedures within 2 weeks and 2cm of the selected treatment area
Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks
Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area
Clareo Health | A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
